A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma
Carregando...
Citações na Scopus
82
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
LABGAA, Ismail
VILLACORTA-MARTIN, Carlos
D'AVOLA, Delia
CRAIG, Amanda J.
FELDEN, Johann von
SIA, Daniela
STUECK, Ashley
WARD, Stephen C.
FIEL, M. Isabel
Citação
ONCOGENE, v.37, n.27, p.3740-3752, 2018
Resumo
Cellular components of solid tumors including DNA are released into the bloodstream, but data on circulating-free DNA (cfDNA) in hepatocellular carcinoma (HCC) are still scarce. This study aimed at analyzing mutations in cfDNA and their correlation with tissue mutations in patients with HCC. We included 8 HCC patients treated with surgical resection for whom we collected paired tissue and plasma/serum samples. We analyzed 45 specimens, including multiregional tumor tissue sampling (n = 24), peripheral blood mononuclear cells (PMBC, n = 8), plasma (n = 8) and serum (n = 5). Ultra-deep sequencing (5500x coverage) of all exons was performed in a targeted panel of 58 genes, including frequent HCC driver genes and druggable mutations. Mutations detected in plasma included known HCC oncogenes and tumor suppressors (e.g., TERT promoter, TP53, and NTRK3) as well as a candidate druggable mutation (JAK1). This approach increased the detection rates previously reported for mutations in plasma of HCC patients. A thorough characterization of cis mutations found in plasma confirmed their tumoral origin, which provides definitive evidence of the release of HCC-derived DNA fragments into the bloodstream. This study demonstrates that ultra-deep sequencing of cfDNA is feasible and can confidently detect somatic mutations found in tissue; these data reinforce the role of plasma DNA as a promising minimally invasive tool to interrogate HCC genetics.
Palavras-chave
Referências
- Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364
- [Anonymous], FDA APPR 1 BLOOD TES
- Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
- Cai ZX, 2017, INT J CANCER, V141, P977, DOI 10.1002/ijc.30798
- Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391
- Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
- Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110
- Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261
- De Mattos-Arruda L, 2014, ANN ONCOL, V25, P1729, DOI 10.1093/annonc/mdu239
- Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g
- Huang A, 2017, J HEPATOL, V67, P293, DOI 10.1016/j.jhep.2017.03.005
- Huang A, 2016, J CANCER, V7, P1907, DOI 10.7150/jca.15823
- Izumchenko E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9258
- Jiang PY, 2015, P NATL ACAD SCI USA, V112, pE1317, DOI 10.1073/pnas.1500076112
- Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113
- Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111
- Labgaa I, 2015, DISCOV MED, V19, P263
- Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
- Liao WJ, 2016, ONCOTARGET, V7, P40481, DOI 10.18632/oncotarget.9629
- Lin XJ, 2015, LANCET ONCOL, V16, P804, DOI 10.1016/S1470-2045(15)00048-0
- Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]
- Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
- Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
- Malapelle U, 2017, BRIT J CANCER, V116, P802, DOI 10.1038/bjc.2017.8
- MANDEL P, 1948, C R Seances Soc Biol Fil, V142, P241
- McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
- Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065
- Newman AM, 2016, NAT BIOTECHNOL, V34, P547, DOI 10.1038/nbt.3520
- Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519
- Norton ME, 2015, NEW ENGL J MED, V372, P1589, DOI 10.1056/NEJMoa1407349
- Ono A, 2015, CELL MOL GASTROENTER, V1, P516, DOI 10.1016/j.jcmgh.2015.06.009
- Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283
- Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252
- Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870
- Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219
- Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126
- Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43
- Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333
- Zhai WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14565
- Zill OA, 2015, CANCER DISCOV, V5, P1040, DOI 10.1158/2159-8290.CD-15-0274